Recent Reports

ICER’s report on the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM, Novartis) and axicabtagene ciloleucel (YescartaTM, Kite Pharma/Gilead). This report will be subject to public deliberation during a meeting of CTAF on March 2, 2018.

View More on this Topic

ICER’s final report on voretigene neparvovec for RPE65-mediated retinal disease.

Click “View” to download a Word version of the report. A PDF version is available here (recommended for viewing on mobile devices).

View More on this Topic

ICER’s final report assessing VMAT2 inhibitors for treatment of tardive dyskinesia.

View More on this Topic

Materials

New England CEPAC

Psoriasis Update: Research Protocol

New England CEPAC

Psoriasis Update: Model Analysis Plan

CTAF

CAR-T Therapies: ICER’s Response to Comments

CTAF

CAR-T Therapies: Revised Voting Questions

Midwest CEPAC

Voretigene Neparvovec: Report-at-a-Glance

Midwest CEPAC

Voretigene Neparvovec: Evidence Presentation

Washington State

Lumbar Fusion: Washington State Final Report

New England CEPAC

Elagolix: Stakeholder List

New England CEPAC

Tardive Dyskinesia: Report-at-a-Glance

CTAF

CAR-T Therapies: Draft Voting Questions

New England CEPAC

Endometriosis: Open Input Period

New England CEPAC

Elagolix: Public Comments on Draft Scoping Document